Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Basic Medicine
  4. Vol 1, Issue 2, 2023

Research progress of sodium-glucose cotransporter 2 inhibitors and autonomic nervous function in patients with heart failure

Download as PDF

DOI: 10.23977/medbm.2023.010210 | Downloads: 3 | Views: 281

Author(s)

Wenjie Li 1, Kaiwen Liu 1, Guipeng Wang 1

Affiliation(s)

1 Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830000, China

Corresponding Author

Guipeng Wang

ABSTRACT

Heart failure (HF) seriously affects human health, and the autonomic nervous system disorder is an important basis for the occurrence and development of heart failure. Sodium-glucose cotransporter 2 inhibitor (SGLT2i) was originally used to treat diabetes. Basic and clinical studies have reported that SGLT2i is effective in reducing the incidence of heart failure, hospitalization, and all-cause mortality in patients with or without diabetes mellitus. Because of its significant cardiovascular benefits, SGLT2i has been used as a guideline in the treatment of heart failure. The mechanisms by which SGLT2i improves heart failure include regulation of volume, cardio-renal mechanism, metabolic action, improvement of myocardial remodeling, reduction of inflammation and oxidative stress. Recent studies have found that SGLT2i is closely related to autonomic nervous function, and may be a new mechanism to improve heart failure. This article focuses on discussing the benefits of SGLT2i on heart failure and its effects on autonomic nervous system, providing a new basis for clinical treatment of heart failure.

KEYWORDS

Heart failure, Sodium-glucose cotransporter 2 inhibitors, Autonomic nervous system

CITE THIS PAPER

Wang Qiutong, Zhang Qiming, Pharmacological Effects of Polygala Tenuifolia and Research Progress on Its Prevention and Treatment of Alzheimer's Disease. MEDS Basic Medicine (2023) Vol. 1: 60-64. DOI: http://dx.doi.org/10.23977/medbm.2023.010210.

REFERENCES

[1] Heidenreich P A, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive  Summary: A Report of the American College of Cardiology/American Heart  Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022,145(18):e876-e894.
[2] Truby L K, Rogers J G. Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches[J]. JACC Heart Fail, 2020,8(7):523-536.
[3] McDonagh T A, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart  failure[J]. Eur Heart J, 2021,42(36):3599-3726.
[4] Manolis A A, Manolis T A, Manolis A S. Neurohumoral Activation in Heart Failure[J]. Int J Mol Sci, 2023,24(20).
[5] Abassi Z, Khoury E E, Karram T, et al. Edema formation in congestive heart failure and the underlying mechanisms[J]. Front Cardiovasc Med, 2022,9:933215.
[6] Zinman B, Wanner C, Lachin J M, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes[J]. N Engl J Med, 2015,373(22):2117-2128.
[7] McMurray J, Solomon S D, Inzucchi S E, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction[J]. N Engl J Med, 2019,381(21):1995-2008.
[8] Solomon S D, McMurray J, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction[J]. N Engl J Med, 2022,387(12):1089-1098.
[9] Sano M, Chen S, Imazeki H, et al. Changes in heart rate in patients with type 2 diabetes mellitus after treatment  with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical  trials[J]. J Diabetes Investig, 2018,9(3):638-641.
[10] Kiuchi S, Hisatake S, Kabuki T, et al. Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report[J]. Drug Discov Ther, 2018,12(1):51-54.
[11] Shimizu W, Kubota Y, Hoshika Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial[J]. Cardiovasc Diabetol, 2020, 19(1):148.
[12] Scholtes R A, Mosterd C M, Hesp A C, et al. Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary  analysis of a randomized crossover trial[J]. Diabetes Obes Metab, 2023,25(1):198-207.
[13] Costanzo M R. The Cardiorenal Syndrome in Heart Failure[J]. Heart Fail Clin, 2020,16(1):81-97.
[14] Fathi A, Vickneson K, Singh J S. SGLT2-inhibitors; more than just glycosuria and diuresis[J]. Heart Fail Rev, 2021, 26(3):623-642.
[15] Perkovic V, Jardine M J, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy[J]. N Engl J Med, 2019,380(24):2295-2306.
[16] Matthews J R, Herat L Y, Magno A L, et al. SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging[J]. Biomedicines, 2020,8(11).
[17] Lam C, Chandramouli C, Ahooja V, et al. SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects[J]. J Am Heart Assoc, 2019,8(20):e013389.
[18] Pawlos A, Broncel M, Woźniak E, et al. Neuroprotective Effect of SGLT2 Inhibitors[J]. Molecules, 2021,26(23).
[19] Nguyen T, Wen S, Gong M, et al. Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice[J]. Diabetes Metab Syndr Obes, 2020,13:2781-2799.
[20] Lopaschuk G D, Karwi Q G, Tian R, et al. Cardiac Energy Metabolism in Heart Failure[J]. Circ Res, 2021, 128(10):1487-1513.
[21] Santos-Gallego C G, Requena-Ibanez J A, San A R, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics[J]. J Am Coll Cardiol, 2019, 73(15): 1931-1944.
[22] Oh C M, Cho S, Jang J Y, et al. Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure[J]. Korean Circ J, 2019,49(12):1183-1195.
[23] Oldgren J, Laurila S, Åkerblom A, et al. Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study[J]. Diabetes Obes Metab, 2021,23(7):1505-1517.
[24] Faridvand Y, Kazemzadeh H, Vahedian V, et al. Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation[J]. Clin Exp Pharmacol Physiol, 2022,49(6):643-651.
[25] Koyani C N, Plastira I, Sourij H, et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation[J]. Pharmacol Res, 2020,158:104870.
[26] Kim S R, Lee S G, Kim S H, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease[J]. Nat Commun, 2020,11(1):2127.
[27] Yeves A M, Ennis I L. Na(+)/H(+) exchanger and cardiac hypertrophy[J]. Hipertens Riesgo Vasc, 2020,37(1):22-32.
[28] Al-Shamasi A A, Elkaffash R, Mohamed M, et al. Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases[J]. Int J Mol Sci, 2021, 22(23).

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 427
Visits: 13282

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.